Seroatlas · Human Serome Atlas

UBE2V2

Ubiquitin-conjugating enzyme E2 variant 2

Also known as: DDVit-1, DDVIT1, EDAF-1, EDPF-1, EDPF1, MMS2, UB2V2_HUMAN, UEV-2, UEV2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q15819
Gene: UBE2V2
Ensembl: ENSG00000169139
Chromosome: 8
Canonical length: 145 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm

OverviewNCBI Gene

Ubiquitin-conjugating enzyme E2 variant proteins constitute a distinct subfamily within the E2 protein family. They have sequence similarity to other ubiquitin-conjugating enzymes but lack the conserved cysteine residue that is critical for the catalytic activity of E2s. The protein encoded by this gene also shares homology with ubiquitin-conjugating enzyme E2 variant 1 and yeast MMS2 gene product. It may be involved in the differentiation of monocytes and enterocytes. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

145 residues, UniProt reviewed canonical sequence.

>Q15819|UBE2V2
     1  MAVSTGVKVP RNFRLLEELE EGQKGVGDGT VSWGLEDDED MTLTRWTGMI IGPPRTNYEN
    61  RIYSLKVECG PKYPEAPPSV RFVTKINMNG INNSSGMVDA RSIPVLAKWQ NSYSIKVVLQ
   121  ELRRLMMSKE NMKLPQPPEG QTYNN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against UBE2V2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.32
Highest tissue expression: 30 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 30 nTPM
skeletal muscle: 27 nTPM
liver: 25 nTPM
tongue: 23 nTPM
retina: 20 nTPM
esophagus: 19 nTPM

Single-cell type

esophageal apical cells: 401 nCPM
esophageal suprabasal cells: 293 nCPM
megakaryocytes: 229 nCPM
syncytiotrophoblasts: 192 nCPM
extravillous trophoblasts: 186 nCPM
late primary spermatocytes: 170 nCPM

Immune cell

NK-cell: 53 nTPM
T-reg: 45 nTPM
total PBMC: 41 nTPM
intermediate monocyte: 41 nTPM
myeloid DC: 40 nTPM
naive CD8 T-cell: 38 nTPM

Brain region

cerebral cortex: 34 nTPM
thalamus: 33 nTPM
pons: 32 nTPM
hypothalamus: 31 nTPM
midbrain: 31 nTPM
medulla oblongata: 30 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.25
gnomAD pLI: 0.03
gnomAD missense Z: 1.33
DepMap mean gene effect: -0.14
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 15% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of UBE2V2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads UBE2V2 as an antibody target. Whether an autoantibody or antibody against UBE2V2 could matter depends on whether native UBE2V2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

UBE2V2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label UBE2V2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...